According to ImmunoGen 's latest financial reports the company's current EPS (TTM) is -HK$2.41. In 2022 the company made an earnings per share (EPS) of -HK$6.85 a decrease over its 2021 EPS that were of -HK$5.22.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -HK$2.43 | -64.59% |
2022 | -HK$6.85 | 31.34% |
2021 | -HK$5.22 | 148.15% |
2020 | -HK$2.10 | -61.97% |
2019 | -HK$5.53 | -41.32% |
2018 | -HK$9.42 | 18.63% |
2017 | -HK$7.94 | -42.7% |
2016 | -HK$13.86 | 29.93% |
2015 | -HK$10.67 | 61.18% |
2014 | -HK$6.62 | 129.73% |
2013 | -HK$2.88 | -66.96% |
2012 | -HK$8.72 | 27.27% |
2011 | -HK$6.85 | 7.32% |
2010 | -HK$6.39 | 7.89% |
2009 | -HK$5.92 | -16.48% |
2008 | -HK$7.09 | 133.33% |
2007 | -HK$3.04 | -13.33% |
2006 | -HK$3.50 | 25% |
2005 | -HK$2.80 | 176.92% |
2004 | -HK$1.01 | -68.29% |
2003 | -HK$3.19 | -14.58% |
2002 | -HK$3.74 | 118.18% |
2001 | -HK$1.71 | -40.54% |
2000 | -HK$2.88 | -1205.1% |
1999 | HK$0.26 | -110.15% |
1998 | -HK$2.57 | -43.1% |
1997 | -HK$4.52 | -40.82% |
1996 | -HK$7.63 |